AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence

The Indian pharma sector is evolving beyond generics, with AI adoption signaling a shift towards high-value drug discovery. This could lead to re-rating opportunities for innovative players.

Maintain a bullish bias on pharma, focusing on companies investing in R&D and AI, with a stop-loss below recent support levels.

For Indian markets, this story mainly matters for the Pharmaceuticals, Information Technology pocket. The current signal is bullish, so traders should watch whether the effect spreads across the sector or stays limited to a single name.

Watch whether the next market session confirms the setup described here: Increased adoption of AI is expected to drive efficiency, innovation, and potentially higher margins across the sector. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Indian drug giants are 'betting big' on Artificial Intelligence.
• •AI is being utilized in drug discovery and development processes.
• •The move aims to enhance efficiency and innovation within the pharma sector.
• •Risk flag: High R&D costs associated with AI integration may impact near-term profitability.
• •Risk flag: Regulatory hurdles and ethical considerations for AI in drug development.